Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Idexx Laboratories (IDXX)

IDEXX Q4 revenue rises 14% to $1,091 million; 2026 EPS guidance $14.29-$14.80

Positive Impact 3 of 5 earnings Written later

IDEXX reported fourth quarter 2025 revenue of $1,091 million, up 14% as reported and 12% organic, and fourth quarter EPS of $3.08, up 18%. The company also gave initial 2026 guidance of $4,632 million to $4,720 million in revenue and $14.29 to $14.80 in EPS, which would represent reported EPS growth of 9% to 13%.

Key points

  • Q4 2025 revenue $1,091 million, up 14% as reported and 12% organic; CAG Diagnostics recurring revenue up 12% as reported
  • Q4 2025 EPS $3.08, up 18% as reported and 17% comparable; operating margin 28.9%, up 150 basis points as reported
  • Full-year 2025 revenue $4,304 million, up 10%; full-year EPS $13.08, up 23% as reported and 14% comparable
  • 2026 outlook: revenue $4,632 million to $4,720 million; EPS $14.29 to $14.80; operating margin 32.0% to 32.5%

The filing

CompanyIdexx Laboratories (IDXX)
Form8-K, current report
Filed with the SECFeb 2, 2026, 6:39 AM ET
Accession number0001104659-26-008904

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.